Cadila Healthcare Ltd., the flagship firm of India's Zydus Cadila group, has entered the league of companies researching interleukin (IL) therapies through a tie-up with Emeryville, California-based Xoma Corp. for an immuno-oncology (IO) drug candidate that combines Zydus’s IL-2 product with XOMA’s novel anti-IL-2 monoclonal antibody.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?